Second-generation compound for the modulation of utrophin in the therapy of DMD

Human Molecular Genetics

Volumn 24, Issue 15, 2015, Pages 4212-4224

  Guiraud, Simon ^a   Squire, Sarah E ^a   Edwards, Benjamin ^a   Chen, Huijia ^a   Burns, David T ^a   Shah, Nandini ^a   Babbs, Arran ^a   Davies, Stephen G ^b   Wynne, Graham M ^b   Russell, Angela J ^a,b   Elsey, David ^c   Wilson, Francis X ^c   Tinsley, Jon M ^c   Davies, Kay E ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c SUMMIT PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; FUSED HETEROCYCLIC RINGS; SMT C1100 DRUG; UNCLASSIFIED DRUG; UTROPHIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 10 MOUSE; CARDIAC MUSCLE; CELL LINE; CONTROLLED STUDY; DIAPHRAGM; DUCHENNE MUSCULAR DYSTROPHY; FIBROSIS; GENE MUTATION; H2K-MDX UTARNA-LUC CELL LINE; HEART; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUCIFERASE ASSAY; MALE; METABOLISM; MOUSE; MUSCLE CONTRACTION; MUSCLE FUNCTION; NECROSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PHYSICAL CHEMISTRY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; SOLEUS MUSCLE; STATISTICAL ANALYSIS; SYNAPSE; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MUSCLE; MUSCULAR DYSTROPHY, DUCHENNE; PATHOLOGY; SARCOLEMMA; SKELETAL MUSCLE CELL; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; DYSTROPHIN; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCLE FIBERS, SKELETAL; MUSCLES; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; SARCOLEMMA; UTROPHIN;

EID: 85018215091     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv154     Document Type: Article

References (82)

1. Cohn, R.D. and Campbell, K.P. (2000) Molecular basis of muscular dystrophies. Muscle Nerve, 23, 1456–1471.
2. Dickson, G., Love, D.R., Davies, K.E., Wells, K.E., Piper, T.A. and Walsh, F.S. (1991) Human dystrophin gene transfer: production and expression of a functional recombinant DNA-based gene. Hum. Genet., 88, 53–58.
3. Emery, A.E. (1993) Duchenne muscular dystrophy–Meryon’s disease. Neuromusc. Disord., 3, 263–266.
4. Bogdanovich, S., Perkins, K.J., Krag, T.O. and Khurana, T.S. (2004) Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. J. Mol. Med., 82, 102–115.
5. Bach, J.R., O’Brien, J., Krotenberg, R. and Alba, A.S. (1987) Management of end stage respiratory failure in Duchenne muscular dystrophy. Muscle Nerve, 10, 177–182.
6. Davies, K.E. and Nowak, K.J. (2006) Molecular mechanisms of muscular dystrophies: old and new players. Nat. Rev. Mol. Cell. Biol., 7, 762–773.
7. Emery, A.E. (1990) Dystrophin function. Lancet, 335, 1289.
8. Voit, T., Topaloglu, H., Straub, V., Muntoni, F., Deconinck, N., Campion, G., De Kimpe, S.J., Eagle, M., Guglieri, M., Hood, S. et al. (2014) Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol., 13, 987–996.
9. Goyenvalle, A., Griffith, G., Babbs, A., Andaloussi, S.E., Ezzat, K., Avril, A., Dugovic, B., Chaussenot, R., Ferry, A., Voit, T. et al. (2015) Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat. Med., 21, 270–275.
10. Finkel, R.S., Flanigan, K.M., Wong, B., Bonnemann, C., Sampson, J., Sweeney, H.L., Reha, A., Northcutt, V.J., Elfring, G., Barth, J. et al. (2013) Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One, 8, e81302.
11. Wang, Z., Storb, R., Halbert, C.L., Banks, G.B., Butts, T.M., Finn, E.E., Allen, J.M., Miller, A.D., Chamberlain, J.S. and Tapscott, S. J. (2012) Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol. Ther. J. Am. Soc. Gene Ther., 20, 1501–1507.
12. Nik-Ahd, F. and Bertoni, C. (2014) Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single stranded oligodeoxynucleotides induces stable expression of dystrophin in a mouse model for Duchenne muscular dystrophy. Stem Cells, 32, 1817–1830.
13. Nelson, M.D., Rader, F., Tang, X., Tavyev, J., Nelson, S.F., Miceli, M.C., Elashoff, R.M., Sweeney, H.L. and Victor, R.G. (2014) PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology, 82, 2085–2091.
14. Mendell, J.R., Sahenk, Z., Malik, V., Gomez, A.M., Flanigan, K.M., Lowes, L.P., Alfano, L.N., Berry, K., Meadows, E., Lewis, S. et al. (2015) A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol. Ther. J. Am. Soc. Gene Ther., 23, 192–201.
15. Tinsley, J., Robinson, N. and Davies, K.E. (2015) Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzox-azole utrophin modulator, following singleand multiple-dose administration to healthy male adult volunteers. J. Clin. Pharm., 55, 698–707.
16. Love, D.R., Hill, D.F., Dickson, G., Spurr, N.K., Byth, B.C., Mars-den, R.F., Walsh, F.S., Edwards, Y.H. and Davies, K.E. (1989) An autosomal transcript in skeletal muscle with homology to dystrophin. Nature, 339, 55–58.
17. Clerk, A., Morris, G.E., Dubowitz, V., Davies, K.E. and Sewry, C.A. (1993) Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle. Histochem. J., 25, 554–561.
18. Tome, F.M., Matsumura, K., Chevallay, M., Campbell, K.P. and Fardeau, M. (1994) Expression of dystrophin-associated glycoproteins during human fetal muscle development: a preliminary immunocytochemical study. Neuromusc. Disord., 4, 343–348.
19. Schofield, J., Houzelstein, D., Davies, K., Buckingham, M. and Edwards, Y.H. (1993) Expression of the dystrophin-related protein (utrophin) gene during mouse embryogenesis. Dev. Dyn., 198, 254–264.
20. Nguyen, T.M., Ellis, J.M., Love, D.R., Davies, K.E., Gatter, K.C., Dickson, G. and Morris, G.E. (1991) Localization of the DMDL gene-encoded dystrophin-related protein using a panel of nineteen monoclonal antibodies: presence at neuromuscular junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other smooth muscles, and in proliferating brain cell lines. J. Cell Biol., 115, 1695–1700.
21. Helliwell, T.R., Man, N.T., Morris, G.E. and Davies, K.E. (1992) The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies. Neuromusc. Disord., 2, 177–184.
22. Schofield, J.N., Gorecki, D.C., Blake, D.J., Davies, K. and Edwards, Y.H. (1995) Dystroglycan mRNA expression during normal and mdx mouse embryogenesis: a comparison with utrophin and the apo-dystrophins. Dev. Dyn., 204, 178–185.
23. Tinsley, J., Deconinck, N., Fisher, R., Kahn, D., Phelps, S., Gillis, J.M. and Davies, K. (1998) Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat. Med., 4, 1441–1444.
24. Squire, S., Raymackers, J.M., Vandebrouck, C., Potter, A., Tinsley, J., Fisher, R., Gillis, J.M. and Davies, K.E. (2002) Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. Hum. Mol. Genet., 11, 3333–3344.
25. Fisher, R., Tinsley, J.M., Phelps, S.R., Squire, S.E., Townsend, E. R., Martin, J.E. and Davies, K.E. (2001) Non-toxic ubiquitous over-expression of utrophin in the mdx mouse. Neuromuscul. Disord., 11, 713–721.
26. Chakravarty, D., Chakraborti, S. and Chakrabarti, P. (2015) Flexibility in the N-terminal actin-binding domain: clues from in silico mutations and molecular dynamics. Proteins, 83, 696–710.
27. Belanto, J.J., Mader, T.L., Eckhoff, M.D., Strandjord, D.M., Banks, G.B., Gardner, M.K., Lowe, D.A. and Ervasti, J.M. (2014) Microtubule binding distinguishes dystrophin from utrophin. Proc. Natl Acad. Sci. USA, 111, 5723–5728.
28. Gillis. (2002) Multivariate evaluation of the functional recovery obtained by the overexpression of utrophin in skeletal muscles of the mdx mouse. Neuromusc. Disord., 28, S90–S94.
29. Li, D., Bareja, A., Judge, L., Yue, Y., Lai, Y., Fairclough, R., Davies, K.E., Chamberlain, J.S. and Duan, D. (2010) Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. J. Cell. Sci., 123, 2008–2013.
30. Van den Bergen, J.C., Wokke, B.H., Hulsker, M.A., Verschuuren, J.J. and Aartsma-Rus, A.M. (2015) Studying the role of dystrophin-associated proteins in influencing Becker muscular dystrophy disease severity. Neuromusc. Disord., 25, 231–237.
31. Ramachandran, J., Schneider, J.S., Crassous, P.A., Zheng, R., Gonzalez, J.P., Xie, L.H., Beuve, A., Fraidenraich, D. and Peluffo, R.D. (2013) Nitric oxide signalling pathway in Duchenne muscular dystrophy mice: up-regulation of L-arginine transporters. Biochem. J., 449, 133–142.
32. Kleopa, K.A., Drousiotou, A., Mavrikiou, E., Ormiston, A. and Kyriakides, T. (2006) Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy. Hum. Mol. Genet., 15, 1623–1628.
33. Rafael, J.A., Tinsley, J.M., Potter, A.C., Deconinck, A.E. and Davies, K.E. (1998) Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat. Genet., 19, 79–82.
34. Krag, T.O., Bogdanovich, S., Jensen, C.J., Fischer, M.D., Hansen-Schwartz, J., Javazon, E.H., Flake, A.W., Edvinsson, L. and Khurana, T.S. (2004) Heregulin ameliorates the dystrophic phenotype in mdx mice. Proc. Natl Acad. Sci. USA, 101, 13856–13860.
35. Sonnemann, K.J., Heun-Johnson, H., Turner, A.J., Baltgalvis, K.A., Lowe, D.A. and Ervasti, J.M. (2009) Functional substitution by TAT-utrophin in dystrophin-deficient mice. PLoS Med., 6, e1000083.
36. Chakkalakal, J.V., Miura, P., Belanger, G., Michel, R.N. and Jasmin, B.J. (2008) Modulation of utrophin A mRNA stability in fast versus slow muscles via an AU-rich element and calcineurin signaling. Nucl. Acid. Res., 36, 826–838.
37. Moorwood, C., Soni, N., Patel, G., Wilton, S.D. and Khurana, T.S. (2013) A cell-based high-throughput screening assay for posttranscriptional utrophin upregulation. J. Biomol. Screen., 18, 400–406.
38. Gilbert, R., Nalbanoglu, J., Tinsley, J.M., Massie, B., Davies, K.E. and Karpati, G. (1998) Efficient utrophin expression following adenovirus gene transfer in dystrophic muscle. Biochem. Biophys. Res. Comms., 242, 244–247.
39. Wakefield, P.M., Tinsley, J.M., Wood, M.J., Gilbert, R., Karpati, G. and Davies, K.E. (2000) Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene. Gene Ther., 7, 201–204.
40. Amenta, A.R., Yilmaz, A., Bogdanovich, S., McKechnie, B.A., Abedi, M., Khurana, T.S. and Fallon, J.R. (2011) Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc. Natl Acad. Sci. USA, 108, 762–767.
41. Tinsley, J.M., Fairclough, R.J., Storer, R., Wilkes, F.J., Potter, A.C., Squire, S.E., Powell, D.S., Cozzoli, A., Capogrosso, R.F., Lambert, A. et al. (2011) Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One, 6, e19189.
42. D’Arcy, C.E., Feeney, S.J., McLean, C.A., Gehrig, S.M., Lynch, G. S., Smith, J.E., Cowling, B.S., Mitchell, C.A. and McGrath, M.J. (2014) Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy. Hum. Mol. Genet., 23, 618–636.
43. Chancellor, D.R., Davies, K.E., De Moor, O., Dorgan, C.R., Johnson, P.D., Lambert, A.G., Lawrence, D., Lecci, C., Maillol, C., Middleton, P.J. et al. (2011) Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy. J. Med. Chem., 54, 3241–3250.
44. Miura, P. and Jasmin, B.J. (2006) Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we? Trends Mol. Med., 12, 122–129.
45. Koo, J.H., Smiley,, M.A., Lovering, R.M. and Margolis, F.L. (2007) Bex1 knock out mice show altered skeletal muscle regeneration. Biochem. Biophys. Res. Comms., 363, 405–410.
46. Chakkalakal, J.V., Stocksley, M.A., Harrison, M.A., Angus, L.M., Deschenes-Furry, J., St-Pierre, S., Megeney, L.A., Chin, E.R., Michel, R.N. and Jasmin, B.J. (2003) Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling. Proc. Natl Acad. Sci. USA, 100, 7791–7796.
47. Banks, G.B., Combs, A.C., Odom, G.L., Bloch, R.J. and Chamberlain, J.S. (2014) Muscle structure influences utrophin expression in mdx mice. PLoS Genet., 10, e1004431.
48. Bulfield, G., Siller, W.G., Wight, P.A. and Moore, K.J. (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl Acad. Sci. USA, 81, 1189–1192.
49. McGeachie, J.K., Grounds, M.D., Partridge, T.A. and Morgan, J. E. (1993) Age-related changes in replication of myogenic cells in mdx mice: quantitative autoradiographic studies. J. Neurolog. Scs., 119, 169–179.
50. Ozawa, E. (1995) [Dystrophin, dystrophin-associated protein and dystrophinopathy]. Nihon Shinkei Seishin Yakurigaku Zasshi: Jpn. J. Psychopharmacol., 15, 289–293.
51. Stedman, H.H., Sweeney, H.L., Shrager, J.B., Maguire, H.C., Panettieri, R.A., Petrof, B., Narusawa, M., Leferovich, J.M., Sladky, J.T. and Kelly, A.M. (1991) The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature, 352, 536–539.
52. Matecki, S., Guibinga, G.H. and Petrof, B.J. (2004) Regenerative capacity of the dystrophic (mdx) diaphragm after induced injury. Am. J. Phy. Reg. Integr. Com. Phys., 287, R961–R968.
53. Hnia, K., Tuffery-Giraud, S., Vermaelen, M., Hugon, G., Chazalette, D., Masmoudi, A., Rivier, F. and Mornet, D. (2006) Pathological pattern of Mdx mice diaphragm correlates with gradual expression of the short utrophin isoform Up71. Biochim. Biophys. Acta, 1762, 362–372.
54. Dupont-Versteegden, E.E. and McCarter, R.J. (1992) Differential expression of muscular dystrophy in diaphragm versus hindlimb muscles of mdx mice. Muscle Nerve, 15, 1105–1110.
55. Louboutin, J.P., Fichter-Gagnepain, V., Thaon, E. and Fardeau, M. (1993) Morphometric analysis of mdx diaphragm muscle fibres. Comparison with hindlimb muscles. Neuromusc. Dis., 3, 463–469.
56. Coirault, C., Pignol, B., Cooper, R.N., Butler-Browne, G., Chabrier, P.E. and Lecarpentier, Y. (2003) Severe muscle dysfunction precedes collagen tissue proliferation in mdx mouse diaphragm. J. App. Phy., 94, 1744–1750.
57. Gosselin, L.E., Williams, J.E., Deering, M., Brazeau, D., Koury, S. and Martinez, D.A. (2004) Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. Muscle Nerve, 30, 645–653.
58. Gosselin, L.E., Williams, J.E., Personius, K. and Farkas, G.A. (2007) A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone. Muscle Nerve, 35, 208–216.
59. Tan, N. and Lansman, J.B. (2014) Utrophin regulates modal gating of mechanosensitive ion channels in dystrophic skeletal muscle. J. Phys., 592, 3303–3323.
60. Muntoni, F. (2003) Cardiomyopathy in muscular dystrophies. Curr. Opin. Neurol., 16, 577–583.
61. Li, W., Liu, W., Zhong, J. and Yu, X. (2009) Early manifestation of alteration in cardiac function in dystrophin deficient mdx mouse using 3D CMR tagging. J. Cardiovasc. Mag. Reson., 11, 40.
62. Quinlan, J.G., Hahn, H.S., Wong, B.L., Lorenz, J.N., Wenisch, A. S. and Levin, L.S. (2004) Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromusc. Disord., 14, 491–496.
63. Ljubicic, V. and Jasmin, B.J. (2013) AMP-activated protein kinase at the nexus of therapeutic skeletal muscle plasticity in Duchenne muscular dystrophy. Trend. Mol. Med., 19, 614–624.
64. Al-Rewashdy, H., Ljubicic,, V., Lin, W., Renaud, J.M. and Jasmin, B.J. (2014) Utrophin A is essential in mediating the functional adaptations of mdx mouse muscle following chronic AMPK activation. Hum. Mol. Genet., 24, 1243–1255.
65. Crisp, A., Yin, H., Goyenvalle, A., Betts, C., Moulton, H.M., Seow, Y., Babbs, A., Merritt, T., Saleh, A.F., Gait, M.J. et al. (2011) Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum. Mol. Genet., 20, 413–421.
66. Fong, P.Y., Turner, P.R., Denetclaw, W.F. and Steinhardt, R.A. (1990) Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin. Science, 250, 673–676.
67. Culligan, K., Banville, N., Dowling, P. and Ohlendieck, K. (2002) Drastic reduction of calsequestrin-like proteins and impaired calcium binding in dystrophic mdx muscle. J. App. Phys., 92, 435–445.
68. Altamirano, F., Lopez, J.R., Henriquez, C., Molinski, T., Allen, P. D. and Jaimovich, E. (2012) Increased resting intracellular calcium modulates NF-kappaB-dependent inducible nitric-oxide synthase gene expression in dystrophic mdx skeletal myotubes. J. Biol. Chem., 287, 20876–20887.
69. Millay, D.P., Goonasekera, S.A., Sargent, M.A., Maillet, M., Aronow, B.J. and Molkentin, J.D. (2009) Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism. Proc. Natl Acad. Sci. USA, 106, 19023–19028.
70. Costas, J.M., Nye, D.J., Henley, J.B. and Plochocki, J.H. (2010) Voluntary exercise induces structural remodeling in the hearts of dystrophin-deficient mice. Muscle Nerve, 42, 881–885.
71. Vianello, S., Bouyon, S., Benoit, E., Sebrie, C., Boerio, D., Herbin, M., Roulot, M., Fromes, Y. and de la Porte, S. (2014) Arginine butyrate per os protects mdx mice against cardiomyopathy, kyphosis and changes in axonal excitability. Neurobiol. Dis, 71, 325–333.
72. Heier, C.R., Damsker, J.M., Yu, Q., Dillingham, B.C., Huynh, T., Van der Meulen, J.H., Sali, A., Miller, B.K., Phadke, A., Scheffer, L. et al. (2013) VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol. Med., 5, 1569–1585.
73. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B. et al. (2012) Fiji: an open-source platform for biological-image analysis. Nat. Method., 9, 676–682.
74. Kennedy, D.J., Vetteth, S., Periyasamy, S.M., Kanj, M., Fedorova, L., Khouri, S., Kahaleh, M.B., Xie, Z., Malhotra, D., Kolodkin, N.I. et al. (2006) Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension, 47, 488–495.
75. Blake, D.J., Hawkes, R., Benson, M.A. and Beesley, P.W. (1999) Different dystrophin-like complexes are expressed in neurons and glia. J. Cell. Biol., 147, 645–658.
76. Blake, D.J., Nawrotzki, R., Peters, M.F., Froehner, S.C. and Davies, K.E. (1996) Isoform diversity of dystrobrevin, the murine 87-kDa postsynaptic protein. J. Biol. Chem., 271, 7802–7810.
77. Pfaffl, M.W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acid. Res., 29, e45.
78. Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402–408.
79. Ramakers, C., Ruijter, J.M., Deprez, R.H.L. and Moorman, A.F.M. (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosc. Lett., 339, 62–66.
80. Barclay, C.J., Woledge, R.C. and Curtin, N.A. (2009) Effects of UCP3 genotype, temperature and muscle type on energy turnover of resting mouse skeletal muscle. Pflugers Archiv., 457, 857–864.
81. Lynch, G.S., Hinkle, R.T. and Faulkner, J.A. (2000) Power output of fast and slow skeletal muscles of mdx (dystrophic) and control mice after clenbuterol treatment. Exp. Phy., 85, 295–299.
82. Brooks, S.V. and Faulkner, J.A. (1988) Contractile properties of skeletal muscles from young, adult and aged mice. J. Phys., 404, 71–82.